TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04113681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Geniculate Artery Embolization
Description: 1. Conscious sedation : midazolam and fentanyl~2. Local anesthesia : Lidocaine 2% subcutaneous~3. Retrograde or anterograde common femoral artery access - 4Fr introducer~4. Sub-therapeutic anticoagulation (heparin 2000 IU IA)~5. Lower extremity arteriography~6. Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~7. If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~8. Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~9. Arteriotomy closure (manual compression or closure device)
Study: NCT02657954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCT
Description: 10-week Compensatory Cognitive Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HCE
Description: 10-week Holistic Cognitive Education
Study: NCT03347747

Intervention type: OTHER
Intervention: Study Photography + Personal & Medical History Collection
Description: 3D facial images taken and complete a detailed study questionnaire

Intervention type: OTHER
Intervention: Study Photography + Personal & Medical History Collection
Description: 3D facial images taken and complete a detailed study questionnaire
Study: NCT03383003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolin
Description: Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amolin
Description: Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid
Description: clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
Study: NCT02901145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab,low dose cyclophosphamide
Description: treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
Study: NCT00953199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
Study: NCT00930683

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 0.1 mg/kg MEDI-546 as a single IV dose

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 0.3 mg/kg MEDI-546 as a single IV dose

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 1.0 mg/kg MEDI-546 as a single IV dose

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 3.0 mg/kg MEDI-546 as a single IV dose

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 10.0 mg/kg MEDI-546 as a single IV dose

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI-546
Description: 20.0 mg/kg MEDI-546 as a single IV dose
Study: NCT04513678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImmunOncoTool Condition
Description: Immunotherapy education + irAE monitoring + Facilitation of patient-provider communication
Study: NCT01914458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Description: Low-dose computed tomography scan
Study: NCT03600090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EOC202
Description: EOC202 will be SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxol will be IV injection
Study: NCT03027063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10,000 steps
Description: Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive the ACC/AHA exercise guidelines
Study: NCT03560245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bryostatin
Description: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
Study: NCT00054925

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal contact (PC)
Description: This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive technology (IT)
Description: The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
Study: NCT03711474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single dose of Dexamethasone IV or Saline IV given within the first hour of surgey
Study: NCT04489693

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory Care Coordinator Team (ACCT)
Description: See arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Care Physician Program (CCP)
Description: see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Care Community & Culture Program (C4P)
Description: see arm description
Study: NCT04338425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice call
Description: Attending surgeons will contact with their patients on the day of surgery after discharge via voice call.
Study: NCT00346177

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cells
Description: Intramyocardial injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Stem Cells
Description: Intramyocardial injections
Study: NCT01547182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Caloric restriction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Caloric restriction
Study: NCT04338425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video call
Description: Attending surgeons will contact with their patients on the day of surgery after discharge via video call (video conferencing application such as FaceTime or Skype)
Study: NCT00337662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 10-20 milligrams (mg), oral, daily, 10 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2-6 mg, oral, daily, for 10 weeks.
Study: NCT01547182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: Walking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Lifting weights
Study: NCT00337662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2-6 mg, oral, daily, 10 weeks
Study: NCT03861806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAS true
Description: Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
Study: NCT03519477

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sano Patient Medication Profile
Description: The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
Study: NCT02990299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth for Diabetes Adherence Support
Description: Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
Study: NCT03861806

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: PAS sham
Description: Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
Study: NCT00621816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroprusside
Description: nitroprusside continuous infusion, dose to be titrated to clinical effect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
Study: NCT03179813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: During the third molar extraction the hydrocortisone solution will be used in the test group

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: During the third molar extraction the saline solution will be used in the control group
Study: NCT02729935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: 40 mg of intravenous parecoxib 30 min before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of saline
Study: NCT02101918

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo computed tomography perfusion imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study: NCT03861585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semantic group
Description: The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial.
Study: NCT00515437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type B (Myobloc)
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: brivaracétam
Description: titration

Intervention type: BIOLOGICAL
Intervention: felbamate
Description: titration

Intervention type: BIOLOGICAL
Intervention: felbamate
Description: titration
Study: NCT03861585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional group
Description: The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial.
Study: NCT00515437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type B (Myobloc)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo to Myobloc
Study: NCT02140710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic treatment
Description: visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
Study: NCT03204058

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral prophylaxis followed by placement of placebo gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Oral prophylaxis followed by placement of rosuvastatin gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral prophylaxis followed by placement of metformin gel
Study: NCT02066896

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lasertherapy
Description: Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Lasertherapy
Description: Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
Study: NCT01576718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDPI
Description: Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent Diskus
Description: Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: lacosamide
Description: titration

Intervention type: BIOLOGICAL
Intervention: lacosamide
Description: titration

Intervention type: BIOLOGICAL
Intervention: rufinamide
Description: titration

Intervention type: BIOLOGICAL
Intervention: rufinamide
Description: titration

Intervention type: BIOLOGICAL
Intervention: gabapentine
Description: titration

Intervention type: BIOLOGICAL
Intervention: gabapentine
Description: titration
Study: NCT01576718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol
Description: A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
Study: NCT01186614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated CPR
Description: Automated CPR utilised by paramedics to facilitate CPR during transport to hospital

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECMO
Description: Insertion of peripheral VA ECMO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Description: Coronary angiography and intervention where necessary will be performed following ECMO insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
Study: NCT02294539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 50mg/amlodipine 5mg
Description: once daily, 1T, PO medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 100mg/amlodipine 5mg
Description: once daily, 1T, PO medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 50mg/Hydrochlorothiazide 12.5mg
Description: once daily, 1T, PO medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100mg/Hydrochlorothiazide 25mg
Description: once daily, 1T, PO medication
Study: NCT01126060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usage of Fibrin sealant
Description: Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Thyroidectomy
Description: surgical removal of bilateral thyroid glands

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: surgical removal of bilateral thyroid glands